Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer: Abstracted from: Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95:361–376.